A mathematical model is described which determines the impact of a schedule of vaccination on the time course of a certain class of diseases. The data are the demographic variables and parameters and age-dependent non-fatal and fatal case rates. Given the age-and time-dependent rates of vaccination including coverage and corresponding efficacies, various schedules may be distinguished by either the absolute numbers of cases and deaths avoided or the numbers of cases and deaths avoided per dose of vaccine. The model was applied to meningo-coccal serogroup C disease in France. The outcomes of six different vaccination schedules were examined. In absolute terms, a schedule in which all individuals aged between 2 and 20 years were vaccinated performed best, but this schedule and that in which only 1-year olds were vaccinated performed equally and best in terms of cases prevented, but not lives saved, per dose.
INTRODUCTION
The determination of the effects of schedules of vaccination is an important aspect of epidemiology and public health management. With the emerging threat of bioterrorism, it is also necessary for governments to know the predicted outcomes of emergency vaccination programmes [1] .
There are two basic types of model that may be employed in demographic and epidemiological modelling. In the more common type, typified by early SIR models such as those of , the time variable is continuous and the model is formulated as a system of differential equations. Examples of such systems of up to ten components, with application to vaccination against carrier-borne diseases such as tuberculosis are summarized in Bailey [3] . Although continuous time models are often used to make predictions in relation to epidemics and the spread of disease [4, 5] , they are difficult to employ when there are several age groups.
Alternatively, the time variable is taken to be discrete and the numbers in different age groups are followed throughout the courses of their lives. This approach is typified by the population growth theory developed by Leslie [6] (see [7] for a succinct summary). The numbers of females of reproductive age were updated from epoch to epoch using mortality and fecundity data and several features of the longterm dynamic evolution of the population were deduced from the so-called Leslie matrix. The advantage of this kind of model is that parameters such as birth and death rates correspond to observable quantities and the variables correspond in a precise way with measurable demographic quantities. However, qualitative analysis of equilibria, bifurcations or asymptotic behaviour is more difficult than with differential equation models.
Because we were concerned with measurable quantities, our approach was to formulate a system of difference equations in order to make as accurate as possible yet practically realizable estimates of the effects of various vaccination programmes under certain assumptions about the dynamic structure of the diseased and non-diseased sections of the population. Furthermore, as there has been much recent interest in the prospects of vaccination against meningococcal disease [8, 9] and several articles have recently appeared on the cost-effectiveness of various vaccination programmes [10] [11] [12] [13] [14] , our method is illustrated in Sections 3 and 4 by estimating future case and death rates for meningococcal disease, given various vaccination schedules. The latter embraces both age-and time-dependent components. These are used in conjunction with coverage rates to define a vaccination matrix V which plays a central role in the projections.
THE MODEL
The population is divided into monthly age groups. Although this subdivision could be finer, the choice of a month seemed appropriate for the chosen application (meningococcal disease). Since the application was designed for humans, those from age 0 to 100 years were included resulting in 1200 age groups, indexed by j. The time-steps were also taken to be months, indexed by k, with the starting value of k=1.
Population with no specific disease and without vaccination
We let N jk be the number of individuals in the j-th age group who are alive at epoch k. the overall population birthrate is b k at epoch k with no account for the age of the parents as this is not relevant in the present calculations. In order to extrapolate census data if needed, the age-dependent population numbers are projected as follows. The youngest age group is
and for j>1,
where I jk and E jk are the total immigration and emigration rates and where the d jk are age and timedependent per capita death rates.
Inclusion of a specific disease and vaccination
For the vaccination of the population, the various population subgroups are as schematized in Figure 1 . All living individuals are assumed to belong initially to the never-vaccinated group. Then they may be successfully vaccinated and enter the nonsusceptible group, or unsuccessfully vaccinated and still prone to the disease with either fatal or nonfatal consequences. Any individual at any time may die from causes other than the disease under consideration and the whole living population at the end of an epoch may contribute to the population birth processes. It is assumed that immunity can only be achieved as the result of successful vaccination or becoming a non-fatal case. If natural immunity or immunity induced by other means, (Troncoso et al. [15] report that that Neisseria lactamica may confer immunity to Neisseria meningitidis) is to be included, it may be done by splitting the never-vaccinated group into immune and non-immune. However, vaccination programmes would not distinguish these subgroups.
Definitions of symbols
The following variables are defined thus : A jk is the number of individuals in the j-th age group at epoch k who have never been vaccinated B jk is the number of unsuccessfully vaccinated individuals C jk is the number of nonsusceptibles.
The essential vaccination parameters are contained in the following matrices : V jk , the rate of vaccination of individuals in the j-th age group at epoch k F jk , the corresponding efficacy rate for the vaccine.
To complete the calculations we specify for the given disease, R jk the age and time dependent nonfatal case rates D jk the corresponding fatal case rate.
Recursion formulas
The number of never-vaccinated in the youngest age group consists of all births and is given at epoch k+1 in terms of epoch k quantities by
where 
Here (1xV jx1,k ) is the unvaccinated fraction of the previously unvaccinated who must survive or not become nonfatal cases.
For the unsuccessfully vaccinated we have for j=2, …, 1200,
The nonsusceptibles of the youngest age group are always assumed to be
whereas for j=2, …, 1200 we must have
To complete the calculations we determine the numbers vaccinated for each age group at each epoch
the corresponding number of deaths due to the disease
and the corresponding number of nonfatal cases
The quantities in (5A)-(5C) are summed over j to obtain total numbers in any epoch. The above system of equations is easily programmable with a software package such as MATLAB.
Allowance for carriers
In dynamic models of the evolution of a disease in a population it is often important to distinguish between carriers and non carriers [4] . However, in the present quasi-steady state model, the distinction is not necessary if one assumes that the efficacy of the vaccine is the same for carriers and non-carriers, even if the case rates, l 1 and l 2 , are different for the two groups. Assuming a total population of N, a fraction r of carriers, and a vaccination rate v, the total number of cases is just N[l 1 r+(1xr)l 2 ] without vaccination and (1xv) times this quantity following vaccination. This follows because vaccination is assumed to immunize both susceptible (non-diseased) carriers and susceptible non-carriers.
APPLICATION TO MENINGOCOCCAL DISEASE
There are 12 distinct serogroups of Neisseria meningitidis, those causing most disease being A, B, C, W-135 and Y [16] . In most industrialized countries the most common serogroup responsible for disease is B, followed by C. At the time of writing, there exist capsular polysaccharide vaccines for the serogroups A, C, W-135 and Y but these are not indicated for children below 2 years of age, because they are poorly effective in this age group. Furthermore, these vaccines only provide a duration of protection of no more than 5 years in older children and adults. There is no vaccine for serogroup B, but one may be soon forthcoming with the use of DNA sequencing [17] .
The role of carriers
The bacteria responsible for meningococcal disease are found in a considerable percentage of the population who are carriers but have no illness. Evidently, the bacteria may reside in the nasopharynx without penetrating the body systems [18] . The average carriage rate summed over all identifiable and nontypable serogroups is probably of order 5-10 % [19] with one report claiming that rates were 10% in adults and 30 % in teenagers [16] .
The rates of carriage of Neisseria meningitidis are highly variable and may show dramatic changes when social conditions change. Thus for example, in a group of first-year British college students, the rate of carriage grew from 7% in the population of entering students to 23 % in just 4 days and continued to grow to reach a maximum of 30% after several months [20] . The dynamics of transitions between the carrier state and the non-carrier, undiseased state are however not known. For schoolchildren in Belgium the mean duration of carriage of N. meningitidis was estimated to be about 13 months [18] .
Rates of carriage for serogroup C are usually relatively low, outbreaks of disease being attributed to the rapid spread of virulent strains through susceptible subgroups of the population such as teenagers starting college or university, recruits entering military training camps and infants beginning school or daycare [16] . During such periods there are increased acquisition rates. In a recent study related to the comprehensive vaccination in the UK [21] , the rate of carriage of serogroup C in school students aged between 15 and 17 years was estimated at 0 . 45% in 1999 and 0 . 15 % in the post-vaccination year 2000. In 2000 the carriage rate of 0 . 127 % in vaccinated students was significantly less than the rate of 0 . 342 % in unvaccinated students, the latter figure supporting the idea that there may be some degree of ' herd immunity '.
Since the details of transitions from carrier to diseased or from non-carrier to diseased state were unknown for N. meningitidis it was decided to assume the rates of incidence of fatal and nonfatal cases were given by the available age-dependent rates.
The explicit division of the uninfected population into carriers and noncarriers was ignored. The model assumed a steady state with carriers and noncarriers in equilibrium, and in which the per capita rates of fatal and nonfatal cases was fixed, thus presupposing that these rates were small relative to the overall death and birth rates, so that carriage rates do not change significantly. The latter assumption is valid for meningococcal disease in Western countries where the overall death and birth rates are of the order of 0 . 01 per year, whereas the disease rate is usually of order of 0 . 000 01 per year. With regard to the impact of vaccination, the model implicitly yet heuristically takes account of the distinction between carriers and noncarriers.
Application of the model to serogroup C meningococcal disease
The recently developed capsular polysaccharidecarrier protein conjugate vaccines for invasive disease due to meningococcal serogroup C may be successfully administered to children as young as 2 months of age. Faced with an endemic of invasive meningococcal serogroup C disease, with an elevated incidence in children below 5 years of age and a high casefatality rate among adolescents (15 to 20 years of age), the United Kingdom launched a mass immunization programme for children from 2 months to 17 years of age with capsular polysaccharide-carrier protein vaccines in November 1999. There followed a dramatic decrease in the incidence of serogroup C disease [21, 22] .
Demographic and epidemiological data
The census data for France (www.recensement. insee.fr) at the end of 1999 were first extrapolated for 2 years to give the beginning of 2002 as the start time. The population numbers in yearly age groups and corresponding death rates from 0 to 100 years were converted to monthly figures. The population birth rate was set at the most recently
Vaccination schedules
We examined several schedules of vaccination, some involving narrow age groups and others spanning many years. The age of the recipient also affects frequency of dosage : for this particular vaccine, infants under 6 months receive three doses in successive months, infants between 6 months and 1 year receive two doses, whereas individuals older than 12 months are given only one dose. This has a large effect on the cost of vaccinating in the very young age groups. With certain vaccines there is a possibility that individuals vaccinated as infants may need a booster at a later age (for the case of Hib see [23] ) -this may affect the schedules A and B described below but was not included in the calculations.
The programmes examined were as follows, where we included the two extreme cases O, in which nobody was vaccinated, and R, in which the entire population, from age 1 month to 100 years, was successfully vaccinated with the number of doses appropriate for different ages :
O No vaccination A Three doses at 2, 3 and 4 months B One dose at 12 months C One dose at 1 year, 6 years and 11 years for 5 years, followed by schedule A D One dose at 1 year, 6 years and 11 years for 5 years, followed by schedule B E All individuals from 1 year to 20 years F All individuals from 2 months of age to 20 years R Vaccination of the entire population Note that, for example, in schedule B, the dose at 1 year is taken literally ; that is, vaccination takes place on entering the 13th month of life. It is not assumed to mean all 1-year olds which might usually be interpreted as all infants with ages greater than 12 months and less than 24 months. However, the programme can easily accommodate different interpretations of all one year olds by changing the elements of the vaccination matrix.
Efficacy
The vaccination of an individual may not lead to immunity so that the efficacy, or fraction successfully protected against disease is less than 1. In all of the calculations we have done for Neisseria meningitidis serogroup C, the choices of values for efficacy were guided by reference [24] . Thus for all k, for toddlers,
for between toddler and teenager,
and for teenager and older F jk =0Á97, j>179:
Vaccination matrix and coverage
The vaccination matrix V characterizes the schedule of vaccination. For example, for schedule B, which sees every 1-year-old vaccinated on achieving that age, we put
with all other V jk =0. However, this assumes that every individual in a target group is vaccinated. In practice, this is not the case. For vaccination against meningococcal disease due to serogroup C the actual rate of vaccination in the UK programme depended on the age group [24] . We were guided by the data of Miller et al. [22] and set the coverage at 85% regardless of target group. Thus instead of V 13,k =1, ko1, for schedule B we put V 13,k =0 . 85, ko1, for the nonzero entries. Note that the programme automatically excludes the possibility of multiple vaccinations, (apart from cases where multiple doses are specified) for example at 12 months and at 5 years, as once Tables 1-8 . It was assumed that the vaccination is in fact effective for up to 10 years, although a lesser period of effectiveness could be incorporated by insisting that living previously vaccinated individuals re-enter the susceptible subgroup after a certain number of epochs, possibly in a graded or stochastic fashion.
The results of the tables are also presented graphically as follows. In Figure 2 we show the numbers of deaths due to meningococcal disease serogroup C which are avoided when the various schedules A-F and R are applied without cessation for 10 years. In Figure 3 are shown the corresponding numbers Figure 4 shows the numbers of deaths avoided per million doses of vaccine. Figure 2 enables a rapid consideration as to how the various schedules differ in their consequences with regard to absolute numbers of lives saved. A similar figure may be drawn for cases avoided. Figures 3 and 4 are useful for economic considerations as they yield an assessment of the comparative efficiencies, in terms of cases or deaths avoided per million doses of vaccine, for various schedules.
It is also of interest to examine the time course of monthly case and death rates after a given vaccination programme has been instigated. To save space the only results to be displayed graphically here are for schedule D. Figure 5 shows the age distribution of deaths per month due to meningococcal disease serotype C under this schedule after it has been applied for 1 year, 5 years and 10 years. The death rate for individuals less than 1 year old is always unchanged. After 1 year, there are gaps in the distribution due to the vaccination of the 1, 6 and 11 year olds and after 5 years one can see the widening of the gaps as the vaccinated individuals become older. This continues to 10 years but there is a residual death rate due to the fact that the efficacy is less than 100%.
DISCUSSION AND CONCLUSIONS
We formulated a discrete time model for the effects of vaccination on a certain class of diseases. The class of diseases is quite broad if reasonably accurate case and fatality rates are known as functions of time. However, since these rates may be difficult to predict, the most useful application of the model is to diseases for which the rates are not changing too rapidly. The ideal application is to a population in which the disease afflicts a known fraction in each age group in each time period. However, the model could be extended to diseases where contagion leads to changing infection rates if the latter can be estimated in an susceptible-infected homogeneous mixing framework.
The discrete-time projection method offers the advantages of explicit interpretations for parameters and accurate forecasting. In particular in the present model, vaccination rates, vaccination efficacies, disease incidence both fatal and nonfatal, and death rates from other causes are all age-, and possibly timedependent. The model has been implemented without difficulty with standard mathematical software packages. The model was used to explore the possible effects of vaccinating against meningococcal disease serogroup C in the French population. Six different vaccination schedules were analysed and also the effects of vaccinating the entire population so that a comparison could be made with the 'best case ' scenario.
For each schedule we determined, as functions of time, the number of meningococcal type C deaths avoided, the number of non-fatal cases avoided, the number of doses required, and the number of lives saved and cases avoided per million doses of vaccine, taking into account multiple doses in the youngest age groups. From the latter calculated quantities, if the cost per dose is known as say $X, then the financial cost involved in saving one life or avoiding one case can be determined easily. For example, for schedule A run for 10 years, the cost to save one life is about $400 000X whereas the corresponding cost for schedule E is about $100 000X. Note that the results presented in Figures 2-5 reflect the epidemiology of invasive meningococcal C disease vis a vis the elevated incidence in infants and a peak in mortality in adolescent years.
With regard to a schedule that will maximize the numbers of lives saved and cases avoided, it is clear that the more individuals are vaccinated the better to a certain extent, but that it is important if the number of doses is fixed that vaccinating the age-groups with the greatest incidence will lead to the greatest benefit. If vaccine is in limited supply then the greatest benefit does not necessarily derive from pursuing a schedule that prevents the most cases in absolute terms. The reason seems to be that doses can be wasted on groups with small risk.
Thus, in Figure 1 it can be seen that schedule B (vaccinate at one year) performs worst with zero deaths avoided in the first year, 11 after 5 years and 40 after 10 years. Apart from schedule R (whole population vaccinated) the best in absolute terms of deaths and cases avoided is F, in which all individuals from 2 years to 20 years are vaccinated. In absolute terms, schedules F and E both prevent about 65 % of the maximum attainable, whereas schedules C and D (1 year, 6 years and 11 years for 5 years, followed by A or B respectively) prevent only about 16 % of the maximum number for deaths after 5 years but about 28 % after 10 years.
However, if the total dosage is limited, we should examine the graphs shown in Figures 3 and 4 . In Figure 3 , where the number of cases avoided per dose is graphed, we see that schedule E performs best but that it is very closely mimicked by B, which has the worst rating in absolute terms. Furthermore, schedule D approaches after 7 or so years the efficiency of schedules E and B. Similarly, in Figure 4 , it is seen that on a per number of doses basis, schedule E in which all individuals between 2 and 20 are vaccinated, performs best in terms of deaths avoided due to meningococcal disease type C. The second most effective schedule using this criterion is F for the first 7 years but this is overtaken by D in years 7-10. Interestingly, schedule R is only about 50% as efficient as E.
The difference between the performances in Figures  3 and 4 are due to the fact that the age-distribution of fatal and non-fatal cases are different.
In conclusion, in absolute terms, the best schedule apart from R is E and the worst is B ; but in terms of value per dose, B and E are best and A is worst. The above calculations, although deterministic both with regard to demography and the processes of disease and vaccination, are thus useful in choosing between vaccination schedules with regard to absolute frequencies of cases and deaths due to a disease, or with regard to particular public health criteria for the implementation of a new vaccination schedule. These calculations do not take into account the public and professional susceptibility of any particular vaccination schedule, nor the practicality of integration of any new vaccine into already-established programmes.
